Business Context and Reporting Period
Company: Akers Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 12, 2017
Event: Entry into Material Definitive Agreements regarding warrant exercises.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $724,200 expected from the exercise of 724,200 shares.
- Immediate Cash Inflow: Approximately $387,000 expected by October 16, 2017.
- Shares Issued: 724,200 shares of Common Stock (Exercise Shares).
- Exercise Price Adjustment: Reduced from $1.96 to $1.00 per share to induce exercise.
- Transaction Costs: 6% cash commission paid to Maxim Group LLC on gross proceeds.
- Additional Warrants: New warrants issued for 100% of exercised shares (724,200 shares) at an exercise price of $1.26 per share, exercisable after six months.
Material Changes and Agreements
The Company entered into Warrant Exercise Agreements with holders of warrants issued in March 2017. Key changes include:
- Price Reduction: The exercise price was lowered from $1.96 to $1.00 per share.
- Issuance Moratorium: A 30-day blackout period was established following the Closing Date, prohibiting the issuance of new Common Stock or equivalents, with specific exemptions for employee plans, conversions of existing securities, and strategic acquisitions.
- Registration Status: Original Warrants were registered under Form S-3. Additional Warrants were issued unregistered under Section 4(a)(2) and Rule 506 of Regulation D.
Outlook, Risks, and Contingencies
- Liquidity Impact: The transaction provides immediate and near-term capital infusion to the Company.
- Dilution Risk: The issuance of 724,200 Exercise Shares and an equal number of Additional Warrants represents significant potential dilution to existing shareholders.
- Restrictions: The 30-day moratorium limits the Company's ability to raise additional capital or issue equity for strategic purposes during that window, except under narrow exemptions.
- Emerging Growth Company: The registrant is classified as an emerging growth company.
Investor Verification Checklist
- Verify the final number of shares issued and total proceeds received by December 13, 2017.
- Confirm the impact of the 6% commission on net proceeds.
- Monitor the 30-day moratorium period for any exempted issuances that may affect capital structure.
- Review the terms of the Additional Warrants (Exhibit 4.1) for specific conditions regarding the six-month exercise lock-up.
- Assess the dilution effect of the 1:1 Additional Warrant issuance on future earnings per share.